Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Daisuke Kotani"'
Autor:
Junyan Du, Shun-Ichiro Kageyama, Riu Yamashita, Kosuke Tanaka, Masayuki Okumura, Atsushi Motegi, Hidehiro Hojo, Masaki Nakamura, Hidenari Hirata, Hironori Sunakawa, Daisuke Kotani, Tomonori Yano, Takashi Kojima, Yamato Hamaya, Motohiro Kojima, Yuka Nakamura, Ayako Suzuki, Yutaka Suzuki, Katsuya Tsuchihara, Tetsuo Akimoto
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-13 (2023)
Abstract Radiotherapy (RT) plus immunotherapy is a promising modality; however, the therapeutic effects are insufficient, and the molecular mechanism requires clarification to further develop combination therapies. Here, we found that the RNA virus s
Externí odkaz:
https://doaj.org/article/2c635e8b72ff436290dfe707e7042414
Autor:
Mashiro Okunaka, Daisuke Kotani, Hisashi Fujiwara, Kazuma Sato, Naoto Fujiwara, Saori Mishima, Shingo Sakashita, Takayuki Yoshino, Takeo Fujita, Takashi Kojima
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Docetaxel, cisplatin, and 5-fluorouracil (DCF) combination chemotherapy has been established as one of the standard neoadjuvant therapies for locally advanced esophageal squamous cell carcinoma (ESCC). However, little is known about progn
Externí odkaz:
https://doaj.org/article/29bfe853d82041cea4eb26cffd0c06f2
Autor:
Naoya Sakamoto, Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara, Yoshiaki Nakamura, Daisuke Kotani, Masashi Wakabayashi, Shohei Koyama, Hiroyoshi Nishikawa, Yosuke Tanaka, Shogo Takei, Itaru Endo, Motohiro Kojima, Toshihide Ueno, Hiroyuki Mano, Shota Fukuoka, Yi-Tzu Lin, Hiroki Hara, Shinya Kojima
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background Immune checkpoint inhibitor (ICI) combinations represent an emerging treatment strategies in cancer. However, their efficacy in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer (CRC) is variable. Here, a m
Externí odkaz:
https://doaj.org/article/2be9529f9843474fb27cb25f1bcfd88c
Autor:
Mashiro Okunaka PhD, Daisuke Kotani MD, PhD, Saori Mishima MD, PhD, Maho Nakamura, Akihito Kawazoe MD, PhD, Hideaki Bando MD, PhD, Takayuki Yoshino MD, PhD, Kohei Shitara MD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Purpose: Anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) is the key drug for RAS / BRAF V600E wild-type metastatic colorectal cancer (mCRC). However, anti-EGFR mAb-induced skin fissures often affect a patient’s quality of
Externí odkaz:
https://doaj.org/article/800ea98d6da648fbacb4c6dc3c67532d
Autor:
Hiromichi Nakajima, Daisuke Kotani, Hideaki Bando, Takeshi Kato, Eiji Oki, Eiji Shinozaki, Yu Sunakawa, Kentaro Yamazaki, Satoshi Yuki, Yoshiaki Nakamura, Takeharu Yamanaka, Takayuki Yoshino, Takashi Ohta, Hiroya Taniguchi, Yoshinori Kagawa
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Previous clinical trials have demonstrated the potential efficacy of rechallenge with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) for patients with RAS/BRAF V600E wild-type metastatic colorectal canc
Externí odkaz:
https://doaj.org/article/02b244cb3c0549f99cadc14324637692
Autor:
Mashiro Okunaka, Daisuke Kotani, Ken Demachi, Akihito Kawazoe, Takayuki Yoshino, Toshikatsu Kawasaki, Kohei Shitara
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Nanoparticle albumin-bound paclitaxel (nab-PTX) has shown non-inferiority to paclitaxel (PTX) as second-line therapy for advanced gastric cancer (AGC) with fewer infusion-related reactions. The efficacy and safety of nab-PTX plus
Externí odkaz:
https://doaj.org/article/de783cbf03f74c978acd0ae407459c17
Autor:
Hideaki Bando, Daisuke Kotani, Takahiro Tsushima, Hiroki Hara, Shigenori Kadowaki, Ken Kato, Keisho Chin, Kensei Yamaguchi, Shun-ichiro Kageyama, Hidehiro Hojo, Masaki Nakamura, Hidenobu Tachibana, Masashi Wakabayashi, Miki Fukutani, Yosuke Togashi, Nozomu Fuse, Hiroyoshi Nishikawa, Takashi Kojima
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response (CR) rates are low at 11
Externí odkaz:
https://doaj.org/article/177fd65d37574541bcfba385232aad76
Autor:
Daisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, Asumi Kaneko, Yoshiaki Nakamura, Akihito Kawazoe, Hideaki Bando, Hiroya Taniguchi, Kohei Shitara, Takashi Kojima, Akihito Tsuji, Takayuki Yoshino
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retro
Externí odkaz:
https://doaj.org/article/5353642cd7e043c7a448adae57648b7d
Autor:
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. Methods Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regime
Externí odkaz:
https://doaj.org/article/6bb077a4afc0401982a619dd6d4c130c
Autor:
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, Akihito Kawazoe, Yasutoshi Kuboki, Kohei Shitara, Takashi Kojima, Hiroya Taniguchi, Jun Watanabe, Itaru Endo, Takayuki Yoshino
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, the
Externí odkaz:
https://doaj.org/article/7aab82a13e18448aa87b6df384e86f3f